Compare ENPH & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENPH | GRFS |
|---|---|---|
| Founded | 2006 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.2B |
| IPO Year | 2012 | 2006 |
| Metric | ENPH | GRFS |
|---|---|---|
| Price | $43.25 | $9.29 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 24 | 2 |
| Target Price | ★ $42.89 | $10.15 |
| AVG Volume (30 Days) | ★ 9.7M | 449.6K |
| Earning Date | 02-03-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ 71.77 | N/A |
| EPS | ★ 1.29 | 0.64 |
| Revenue | $1,472,985,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | N/A | $5.36 |
| Revenue Next Year | $10.36 | $5.15 |
| P/E Ratio | $34.22 | ★ $17.85 |
| Revenue Growth | ★ 10.72 | 7.31 |
| 52 Week Low | $25.78 | $6.19 |
| 52 Week High | $70.78 | $11.14 |
| Indicator | ENPH | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 52.06 |
| Support Level | $47.07 | $9.07 |
| Resistance Level | $52.24 | $9.64 |
| Average True Range (ATR) | 3.29 | 0.21 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 47.88 | 42.47 |
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.